{"id":31421,"date":"2026-07-06T21:00:00","date_gmt":"2026-07-06T19:00:00","guid":{"rendered":"http:\/\/stocks-future.com\/?guid=fea6b730c7d68502574a2b87cf2f3155"},"modified":"2026-07-06T21:00:00","modified_gmt":"2026-07-06T19:00:00","slug":"maat-pharma-presents-the-results-of-its-annual-general-meeting-and-provides-a-statement-on-its-half-year-liquidity-contract","status":"publish","type":"post","link":"https:\/\/stocks-future.com\/?p=31421","title":{"rendered":"MaaT Pharma Presents the Results of its Annual General Meeting and Provides a Statement on its Half-Year Liquidity Contract"},"content":{"rendered":"

LYON, France--(BUSINESS WIRE)--$MAAT<\/a> #GeneralMeeting<\/a>--Regulatory News:<\/p><\/a><\/a>

\nMaaT Pharma<\/a> (EURONEXT: MAAT \u2013 the \u201cCompany\u201d), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM <\/sup>(MET) dedicated to enhancing survival for patients with cancer through immune modulation, presents the results of its Annual and Extraordinary General Meeting held on Tuesday, June 16, 2026 at 9:30 am CET at the Company's office and broadcasted live (replay available here<\/a>). The Company also provides an update on the liquidity contract managed by Kepler Cheuvreux as of June 30th<\/sup>, 2026.<\/p>

\nAnnual and Extraordinary General Meeting<\/b><\/span><\/p>

\nThe quorum reached by the shareholders present, representing, or voting remotely, was above 69.61% of voting shares.<\/p>

\nShareholders overwhelmingly approved most of the resolutions put forward by the Board of Directors by a majority of over 90%. The following resolutions were approved:<\/p>